Global Lysosomal Acid Lipase Deficiency (LAL-D) Market - Industry Trends and Forecast to 2030

Análise e dimensão do mercado da deficiência de lipase de ácido lisossómico (LAL-D)

A deficiência de lipase ácida lisossomal (LAL-D), também conhecida como doença de Wolman ou doença de armazenamento de éster de colesterol (CESD), é uma doença genética rara caracterizada por uma deficiência da enzima lipase ácida lisossomal. Esta enzima desempenha um papel crucial na decomposição das gorduras e do colesterol no organismo. Quando deficiente ou não funcional, leva à acumulação de lípidos (gorduras) em diversos tecidos e órgãos, provocando uma vasta gama de sintomas e complicações de saúde. Os avanços nas ferramentas de diagnóstico e nos testes genéticos tornaram mais fácil a identificação e confirmação de casos de LAL-D. O diagnóstico precoce e preciso é crucial para uma gestão eficaz da doença. Ao longo dos anos, tem-se registado um aumento significativo da sensibilização para doenças raras, como a LAL-D, entre os profissionais de saúde, os doentes e o público em geral. Esta maior consciencialização levou a um diagnóstico e tratamento mais precisos da doença.

A Data Bridge Market Research analisa que o mercado (LAL-D) que foi de 612,00 milhões de dólares em 2022, deverá atingir até 1.311,88 milhões de dólares até 2030, e deverá passar por um CAGR de 10,0% durante o período de previsão. Isto indica que o valor de mercado. A “Doença de Wolman de Início Precoce” domina o segmento de tipo do mercado de deficiência de lipase ácida lisossomal (LAL-D) devido ao aumento das empresas farmacêuticas e biofarmacêuticas que investem nas atividades de triagem pré-clínica que as estão a ajudar nas falhas em fase final e para o desenvolvimento de segmento terapêutico. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado da deficiência de lipase de ácido lisossómico (LAL-D)

Definição de mercado

O mercado da deficiência de lipase ácida lisossomal (LAL-D) é o ecossistema comercial e de saúde relacionado com o diagnóstico, tratamento e gestão da deficiência de lipase ácida lisossomal, também conhecida como doença de Wolman ou doença de armazenamento de colesteril éster (CESD) . A LAL-D é uma doença genética rara caracterizada por uma deficiência da enzima lipase ácida lisossomal, que desempenha um papel crucial na decomposição das gorduras e do colesterol no organismo. Quando esta enzima é deficiente ou não funcional, leva à acumulação de lípidos (gorduras) em diversos tecidos e órgãos, provocando uma vasta gama de sintomas e complicações de saúde.

Dinâmica do mercado global da deficiência de lipase de ácido lisossómico (LAL-D)

Motoristas

• Avanços nas tecnologias de diagnóstico

Os avanços nas ferramentas de diagnóstico e nos testes genéticos tornaram mais fácil o diagnóstico de LAL-D. Métodos de diagnóstico mais precisos e acessíveis permitem a identificação precoce dos indivíduos afetados, o que é crucial para uma intervenção atempada.

• Advocacia e Apoio ao Doente

Os grupos de defesa dos doentes e as fundações dedicadas à LAL-D sensibilizam, prestam apoio aos indivíduos afetados e às suas famílias e promovem ativamente a investigação. Os seus esforços ajudam a impulsionar o interesse e o investimento na descoberta de tratamentos eficazes.

Oportunidade

• Evolving Healthcare Landscape

Changes in healthcare systems, such as an increased focus on rare diseases, personalized medicine, and precision diagnostics, contribute to the growth of the LAL-D market. Healthcare providers are better equipped to diagnose and manage rare diseases such as LAL-D.

Moreover, the demand for lysosomal acid lipase deficiency (LAL-D) is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the lysosomal acid lipase deficiency (LAL-D) market in the above mentioned projected timeframe.

Restraint/Challenge

• Long Development Timelines

Developing treatments for rare diseases often involves lengthy research and development timelines, including clinical trial phases. This can delay the availability of therapies for patients who urgently need them.

Recent Developments

• Currently, Alexion Pharma’s Kanuma is the only product approved for LAL-D treatment. Kanuma (sebelipase alfa) is a subcutaneously delivered enzyme replacement treatment(ERT) approved in the EU (September 2015), U.S. (December 2015), and Japan (March 2016) for LAL-D patients
• In addition, the CESD cohort is prescribed statins and other nutritional supplements. Pfizer (Lipitor) and Merck (Zetia) are key players in the statins segment of the CSED market. However, these companies are poised to lose market share on account of significant competition from generics and approval of ERT for both early and late-onset types of this disease.  Unmet needs within the LAL-D space present a strong opportunity to develop novel first-in-class therapies

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Scope

The lysosomal acid lipase deficiency (LAL-D) market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Early Onset Wolman Disease
• Late onset CESD

Treatment

• Enzyme Replacement Therapy
• Lipid-Modifying Agents (Statins)
• Surgery
• Stem Cell Transplantation
• Supportive Care

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Clinics
• Hospitals
• Ambulatory Surgical Centre
• Others

Distribution Channel

• Direct Tender
• Retail Pharmacy
• Hospital Pharmacy
• Others

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Regional Analysis/Insights

The lysosomal acid lipase deficiency (LAL-D) market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-users, and distribution channel as mentioned above.

The countries covered in the lysosomal acid lipase deficiency (LAL-D) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

North America is expected to dominate the lysosomal acid lipase deficiency (LAL-D) market due to rise in the presence of key players and increased funding from public and private entities have augmented drug discovery and development and rise in the volume of expenditure carried out for advancing the technologies available for development of pharmaceuticals in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to rise in the availability of numerous advanced technologies utilized for protein binding in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The lysosomal acid lipase deficiency (LAL-D) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lysosomal acid lipase deficiency (LAL-D) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lysosomal acid lipase deficiency (LAL-D) market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Lysosomal Acid Lipase Deficiency (LAL-D) market Share Analysis

The lysosomal acid lipase deficiency (LAL-D) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to lysosomal acid lipase deficiency (LAL-D) market.

Some of the major players operating in the lysosomal acid lipase deficiency (LAL-D) market are:

• Alexion Pharmaceuticals, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Morepen (India)
• LUPIN (India)
• Triveni Interchem Private Limited (India)
• Lannett (U.S.)
• Hetero Healthcare Limited (India)
• Sun Pharmaceutical Industries Ltd.(India)
• Zydus Cadila (India)
• Sandoz International GmbH (Germany)
• BioCrick BioTech (China)
• Actiza Pharmaceutical Private Limited (India)
• Teva Pharmaceuticals USA, Inc. (U.S.)
• Glenmark Pharmaceutical Inc. (India)
• ANGLE BIO PHARMA (India)
• Accord Healthcare Limited (India)
• AstraZeneca (U.K.)
• Prudence Pharma Chem (India)
• Novadoz Pharmaceuticals (U.S.)
• Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.)
• Perrigo Company plc (Ireland)

SKU-60215